S.3335 - Fair Accountability and Innovative Research Drug Pricing Act of 2016114th Congress (2015-2016)
|Sponsor:||Sen. Baldwin, Tammy [D-WI] (Introduced 09/15/2016)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||Senate - 09/15/2016 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.3335 — 114th Congress (2015-2016)All Information (Except Text)
Introduced in Senate (09/15/2016)
Fair Accountability and Innovative Research Drug Pricing Act of 2016
This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the price of a drug over a 12-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1.
Manufacturers that do not submit a required report are subject to a civil penalty. The Inspector General of HHS must review drug price information to determine compliance. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.